OncoMatch/Clinical Trials/NCT07195682
A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
Is NCT07195682 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies BMS-986506 for renal cell carcinoma.
Treatment: BMS-986506 — This is a first-in-human study of BMS-986506 in participants with advanced Clear Cell Renal Cell Carcinoma (ccRCC). The primary objective of this study is to find out if BMS-986506 is safe and can be tolerated when taken alone by participants with ccRCC.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Renal Cell Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: immunotherapy
at least two different treatment plans in the past, including immunotherapy and a targeted therapy
Must have received: targeted therapy
at least two different treatment plans in the past, including immunotherapy and a targeted therapy
Must have received: anti-PD-1 therapy
at least one standard treatment plan that included both a PD-1/L1 inhibitor and a VEGF-TKI (either together or one after the other)
Must have received: anti-PD-L1 therapy
at least one standard treatment plan that included both a PD-1/L1 inhibitor and a VEGF-TKI (either together or one after the other)
Must have received: VEGFR inhibitor
at least one standard treatment plan that included both a PD-1/L1 inhibitor and a VEGF-TKI (either together or one after the other)
Cannot have received: HIF2A inhibitor
prior treatment with HIF2a inhibitors
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Local Institution - 0006 · Boston, Massachusetts
- Memorial Sloan Kettering Cancer Center · New York, New York
- Local Institution - 0002 · Philadelphia, Pennsylvania
- SCRI Oncology Partners · Nashville, Tennessee
- START San Antonio · San Antonio, Texas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07195682 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior HIF2A inhibitor disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages